Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00734630 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients
A Phase 4 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 4
- Development phase
- 491
- Enrollment target
NCT00734630: Completed Phase 4 study, sponsored by Forest Laboratories.
NCT00734630 is a Phase 4 study that has completed, run by Forest Laboratories. The registered enrollment target is 491 participants, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00734630, a Phase 4 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 491 participants
- Enrollment target
Study Summary
This study will assess blood pressure reduction with nebivolol or placebo in patients taking lisinopril or losartan.
Primary Outcome
Change from Baseline in Mean Seated Trough Cuff Systolic Blood Pressure (SBP) at Week 12, Last Observation Carried Forward (LOCF).
Interventions
- DRUG Placebo
- DRUG nebivolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 491 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-05 |
| Phase | Phase 4 |
What the finished NCT00734630 record still lists
NCT00734630 is an interventional study that assigns participants to a tested intervention. The registered 491 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00734630 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00734630 about?
NCT00734630 is a clinical study titled "Efficacy and Safety of Nebivolol (Added to Lisinopril or Losartan) in Hypertensive Patients". This study will assess blood pressure reduction with nebivolol or placebo in patients taking lisinopril or losartan.
What is the current status of trial NCT00734630?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 491 participants. The study started on 2008-08. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00734630?
The interventions under investigation include: Placebo (DRUG), nebivolol (DRUG).
Who is sponsoring clinical trial NCT00734630?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00734630's enrollment target sits among peer trials
491 179th of 2000 higher than 1,822 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03418961 · 491 participants · Phase 3
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
- NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- NCT06152575 · 492 participants · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia